Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Barchart on MSN2d
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?Headquartered in Cambridge, Massachusetts, Moderna, Inc. (MRNA) is a biotechnology company specializing in messenger RNA ...
Zacks.com on MSN7d
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates ViewModerna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...
Stephen Hoge will now oversee vaccine sales at Moderna, per a Bloomberg report. Elsewhere, Intra-Cellular unveiled an ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...
Australia’s audit office will probe the Morrison government’s $2 billion deal with US pharmaceutical giant Moderna to set up ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
GlobalData on MSN3d
Moderna’s mRESVIA vaccine gains Health Canada approvalModerna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Tenthoff covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Moderna, and Arrowhead Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus ...
The intersection of sports marketing and the pharmaceutical industry offers a dynamic space where brands can leverage ...
The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback